Press Release: Sanofi’s Lunsekimig Met Primary and Key Secondary Endpoints in Phase 2 Respiratory Studies in Asthma and CRSwNP

Why It Matters

The results validate a novel dual‑target approach that could fill a major therapeutic gap in asthma and nasal polyps, strengthening Sanofi’s respiratory pipeline and potentially reshaping the market landscape.

Key Takeaways

• Asthma phase 2b met primary, secondary endpoints, lowered exacerbations
• CRSwNP study reduced polyp size, improved congestion scores
• Safety profile comparable to placebo across respiratory trials
• Atopic dermatitis primary endpoint missed; secondary skin improvements observed
• Lunsekimig moves to phase 2 AIRLYMPUS and phase 3 trials

Pulse Analysis

Sanofi’s lunsekimig leverages a pentavalent Nanobody platform that simultaneously blocks thymic stromal lymphopoietin (TSLP) and interleukin‑13 (IL‑13), two cytokines that drive airway inflammation from upstream and downstream pathways. By targeting both molecules, the drug aims to deliver additive or synergistic effects that traditional single‑target biologics cannot achieve. The AIRCULES phase 2b data, showing fewer asthma exacerbations and measurable gains in pre‑bronchodilator FEV1, address a persistent unmet need: more than half of moderate‑to‑severe asthma patients remain uncontrolled despite existing therapies.

The DUET trial’s success in chronic rhinosinusitis with nasal polyps (CRSwNP) is equally noteworthy because the condition frequently co‑exists with asthma, amplifying disease burden and healthcare costs. Reductions in polyp size and patient‑reported congestion translate into tangible quality‑of‑life improvements, positioning lunsekimig as a potential first‑in‑class option for a population that currently relies on steroids and surgery. Importantly, safety signals remained comparable to placebo across both studies, reinforcing confidence in the molecule’s tolerability profile for chronic use.

Looking ahead, lunsekimig is slated for the AIRLYMPUS phase 2 trial in high‑risk asthma and two pivotal phase 3 studies—PERSEPHONE and THESEUS—targeting broader respiratory indications. If efficacy and safety are confirmed, Sanofi could capture a sizable share of the multi‑billion‑dollar biologics market, challenging incumbents such as GSK’s dupilumab and AstraZeneca’s tezepelumab. The dual‑target strategy also offers a compelling narrative for investors, highlighting innovative pipeline diversification and the potential for premium pricing in a competitive therapeutic arena.